in vivo models

Physio-pathological models
for in vivo studies

in vivo exploration

In vivo functional
exploration platform

in vivo vitro exploration cardiovascular deseases

In vitro / Ex vivo

bioluminescence resonance

Molecular screening
(BRET-based technology)


Cardiomedex is a highly skilled preclinical CRO specialized in the cardiovascular field. Cardiomedex conducts reliable studies that optimize the preclinical development of drug candidates for the treatment of cardiovascular diseases and cardiometabolic complications.

Our large selection of gold standard animal models covers cardiovascular disorders such as:

  • Heart failure with preserved or reduced ejection fraction (HFpEF and HFrEF)
  • Myocardial infarction
  • Cardiac hypertrophy
  • Hypertension
  • Endothelial dysfunction
  • Anthracycline cardiotoxicity

In addition to CRO services, we provide our clients with personalized consulting services in line with the pharma industry’s emerging trends.

Thanks to their extensive experience in drug development, our scientists and clinicians are able to optimize research timelines and productivity. Cardiomedex can also support your projects in terms of drug repurposing / repositioning.

Cardiomedex is located near Toulouse (France) and shares brand new facilities with Physiogenex. Our technical platform is equipped with all the appropriate devices to ensure high-quality CRO services and reliable study results for our clients.

Along with in vivo models, we offer a state-of-the-art platform for functional exploration & pharmacological characterization using ex-vivo and in vitro assays.

img cardiovascular deseases research

Preclinical CRO Services

Cardiomedex’s objective is to provide relevant and innovative animal models reflecting the clinical situation for the purpose of predictive efficacy studies. Lack of medicines to manage cardiac diseases such as HFpEF prompts us to develop translational models with multiple common risk factors such as NASH, diabetic nephropathy, metabolic syndrome, and type 2 diabetes.

Latest News


Cardiomedex to present  NASH hamster model at the AHA 2023

Cardiomedex to present NASH hamster model at the AHA 2023

Join us at the American Heart Association meeting taking place from 10th to 13th November 2023 in Philadelphia, PA, USA. Cardiomedex is very excited to be sharing the latest results confirming the clinical relevance of the diet-Induced Obese NASH Hamsterfor evaluating...

lire plus

Latests publications

  • Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters.
    Briand F, Maupoint J, Brousseau E, Breyner N, Bouchet M, Costard C, Leste-Lasserre T, Petitjean M, Chen L, Chabrat A, Richard V, Burcelin R, Dubroca C, Sulpice T. Metabolism. 2021 Jan 11;117:154707.
  • Liraglutide shows superior cardiometabolic benefits than lorcaserin in a novel free choice diet-induced obese rat model. Eur J Pharmacol. 2020 Sep 5;882:173316
    Briand F, Brousseau E, Maupoint J, Dubroca C, Costard C, Breyner N, Burcelin R, Sulpice T. 2020 Sep 5;882:173316.
  • Neuronal NO synthase mediates phenylephrine induced cardiomyocyte hypertrophy through facilitation of NFAT-dependent transcriptional activity.
    Loyer X, Dubroca C, Branchereau M, Griffith G, Garcia L, Heymes C. Biochem Biophys Rep. 2019 Mar 11;18:100620.

See all publications

They trust US

partners logo cardiomedex